Cartesian Therapeutics, Inc. · NASDAQ:RNAC
Cartesian Therapeutics — Investor Presentation (March 2025)
19 slides from Cartesian Therapeutics's investor presentation, Mar 3, 2025
Slide 1: Pioneering mRNA Cell Therapy for Autoimmunity
Pioneering mRNA Cell Therapy for Autoimmunity March 2025 Exhibit 99.1
Slide 2: Disclosures
Disclosures For the purposes of this notice, the “presentation” that follows shall mean and include the slides that follow, the oral presentation of the slides by members of management of Cartesian Therapeutics, Inc. (the “Company”) or any person on their behalf, any question-and-answer session that
Slide 3: Pioneering mRNA Cell Therapy for Autoimmunity
PIONEERING mRNA CELL THERAPY FOR AUTOIMMUNITY3 Clinical-stage company pioneering mRNA cell therapies designed to expand the reach of cell therapy to autoimmunity • Pipeline of mRNA cell therapies designed to be dosed more reliably and safely in an outpatient setting without lymphodepletion • Descart
Slide 4: Cartesian's mRNA approach is designed to expand the reach of potent cell therapy
PIONEERING mRNA CELL THERAPY FOR AUTOIMMUNITY4 Cartesian’s mRNA approach is designed to expand the reach of potent cell therapy products to address autoimmunity No Lymphodepletion No associated cytopenia, secondary malignancies, or other chemotherapy toxicities Administered Outpatient Convenient dos
Slide 5: Wholly-owned pipeline targets autoimmune disease
Asset Indications Discovery/Preclinical Phase 1 Phase 2 Phase 3 Descartes-08 Autologous mRNA CAR-T Myasthenia Gravis (MG) Systemic Lupus Erythematosus (SLE) Pediatric Autoimmune Diseases* Descartes-15 Autologous mRNA CAR-T Autoimmune Diseases** Wholly-owned pipeline targets autoimmune disease PIONEE
Slide 6: Myasthenia gravis is a rare, progressive autoimmune disease with significant unmet need
PIONEERING mRNA CELL THERAPY FOR AUTOIMMUNITY6 Myasthenia gravis is a rare, progressive autoimmune disease with significant unmet need Current treatments require chronic or frequent administration and have limited durability Characterized by debilitating fatigue and muscle weakness Limbs Respiratory
Slide 7: Deep and durable responses maintained over months in Phase 2b
Deep and durable responses maintained over 12 months in participants treated with Descartes-08 in Phase 2b PIONEERING mRNA CELL THERAPY FOR AUTOIMMUNITY7 Deepening responses observed over time Durable responses observed over time Deepest responses observed in participants without exposure to prior b
Slide 8: AURORA: Randomized double-blind, placebo-controlled Phase 3 trial of Descartes-08
8 AURORA: Randomized double-blind, placebo-controlled Phase 3 trial of Descartes-08 in AChR Ab+ gMG expected to commence in 1H 2025 WK1 Masked Dosing Six weekly doses of Descartes-08 or placebo PRIMARY ENDPOINT • Proportion of participants with MG-ADL improvement of ≥3 points at Month 4, relative to
Slide 9: Descartes-08 in Myasthenia Gravis Phase 2b Results
PIONEERING mRNA CELL THERAPY FOR AUTOIMMUNITY9 Descartes-08 in Myasthenia Gravis Phase 2b Results
Slide 10: Deepening responses observed in participants treated with Descartes-08
Deepening responses observed in participants treated with Descartes-08 PIONEERING mRNA CELL THERAPY FOR AUTOIMMUNITY10 • Average MG-ADL reduction of 5.5 (±1.1) points at Month 4 • 33% of participants achieved minimum symptom expression at Month 6 • 80% of participants reaching Month 12 maintained cl
Slide 11: Deepest responses observed in participants with no prior exposure to complement or FcRn inhibitors
Deepest responses observed in participants with no prior exposure to complement or FcRn inhibitors PIONEERING mRNA CELL THERAPY FOR AUTOIMMUNITY11 • Average MG-ADL reduction of 6.6 (±1.5) points at Month 4 • 57% of participants achieved minimum symptom expression at Month 6 • 100% of participants re
Slide 12: Safety profile supports outpatient administration
PIONEERING mRNA CELL THERAPY FOR AUTOIMMUNITY12 Safety profile supports outpatient administration Descartes-08 (n=20) Placebo (n=16) Grade 1 Grade 2 Grade 3 Grade 1 Grade 2 Grade 3 Headache 7 (35%) 4 (20%) 2 (13%) 3 (19%) Chills 8 (40%) 4 (20%) Nausea 3 (15%) 6 (30%) 1 (6%) 2 (13%) Fever 7 (35%) 4 (
Slide 13: Phase 2a trial update: Descartes-08 retreatment continues to elicit deep and durable responses
Phase 2a trial update: Descartes-08 retreatment continues to elicit deep and durable responses Manuscript submitted for peer review; pre-print available at medRxiv.org. • Three participants retreated to date, two of whom maintain minimum symptom expression 2 years after initial treatment • Third par
Slide 14: Additional Indications and Pipeline
PIONEERING mRNA CELL THERAPY FOR AUTOIMMUNITY14 Additional Indications and Pipeline
Slide 15: Intend to leverage the potential of Descartes-08 across multiple clinical programs
Intend to leverage the potential of Descartes-08 across multiple clinical programs PIONEERING mRNA CELL THERAPY FOR AUTOIMMUNITY15 • Plan to initiate Phase 3 AURORA clinical trial in 1H 2025 • RMAT designation expected to support efficient development plan in collaboration with FDA MG SLE Potential
Slide 16: Descartes-08 has the potential to address pediatric indications
PIONEERING mRNA CELL THERAPY FOR AUTOIMMUNITY16 Descartes-08 has the potential to address pediatric indications, a severely underserved population • Rare Pediatric Disease Designation for DC-08 in juvenile dermatomyositis granted in September 2024 • IND amendment filed to include DC-08 in juvenile S
Slide 17: Descartes-15, a next generation anti-BCMA mRNA CAR-T with >10x potency in preclinical studies
Descartes-15, a next generation anti-BCMA mRNA CAR-T with >10x potency observed in preclinical studies PIONEERING mRNA CELL THERAPY FOR AUTOIMMUNITY17 Potent killing (single target exposure) Persistent killing (multiple exposures) (1:2) (1:8) (1:32) 0 50 100 % S pe ci fic K ill in g DC-15 DC-08 Vehi
Slide 18: Strong financial position: expected to support pipeline through key milestones
PIONEERING mRNA CELL THERAPY FOR AUTOIMMUNITY18 STRONG FINANCIAL POSITION: Expected to Support Pipeline Through Key Milestones * As of 12/31/24. Further includes Series A Non-Voting Convertible Preferred Stock and Series B Non-Voting Convertible Preferred Stock that remain subject to beneficial owne
Slide 19: Cartesian Therapeutics
ze Cartesian. therapeutics
Cartesian Therapeutics — Investor Presentation (March 2025) on 6ix